Mission: To develop highly selective, well tolerated, and highly effective anti-cancer agents, by selectively targeting altered metabolism in cancer cells. Our immediate goal is to improve the quality of life of patients with Pancreatic Cancer, which is the deadliest cancer worldwide and has limited treatment options.

Vision: To extend and enhance the lives of patients with Gastrointestinal (GI) Cancers.

At Rafael Pharmaceuticals, Inc. we are a pioneering, clinical-stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers. Our primary objective is to produce highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues.

 

CPI-613

Rafael Pharmaceutical’s first-in-class clinical lead compound, CPI-613, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies as a single agent, as well as in combination with standard drug therapies, in patients diagnosed with advanced solid tumors or blood cancers. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS).

World Class Team

Innovation in oncology drug development requires a deep well of scientific, medical and business expertise, and we have assembled an unparalleled team of directors and advisors who are working with Rafael to revolutionize anticancer treatment.

Our Board of Directors and Scientific & Medical Advisory Boards are drawn from the highest echelons of oncology and hematology researchers and physicians, and include seasoned managers from the biotech and pharmaceutical sectors.

  • Placeholder

    Chi Van Dang, M.D., Ph.D., Chairman of Rafael’s Scientific and Medical Advisory Boards

    Director of the Abramson Cancer Center of the University of Pennsylvania. Dr. Dang is considered by many to be the world’s leading authority on cancer metabolism. Dr. Dang currently serves as Rafael’s Chairman of the Scientific and Medical Advisory Boards.

  • Placeholder

    Greg Semenza, M.D., Ph.D., Scientific Advisor

    Director, Vascular Program, Institute for Cell Engineering; Professor of Pediatrics, Radiation Oncology and Molecular Radiation Sciences, Biological Chemistry, Medicine, and Oncology at the Johns Hopkins University School of Medicine. Dr. Semenza won the 2016 Lasker Award.

  • Placeholder

    Dafna Bar-Sagi, Ph.D., Scientific Advisor

    Senior Vice President, Vice Dean for Science, Chief Scientific Officer, Professor, Departments of Biochemistry and Molecular Pharmacology, and Medicine, NYU Langone Medical Center

  • Placeholder

    Philip A. Philip, M.D., Ph.D., FRCP, Pancreatic Cancer Advisor

    Professor of Oncology and Pharmacology, Leader, GI and Neuroendocrine Oncology, Vice President of Medical Affairs, Karmanos Cancer Center, Wayne State University, Detroit, MI.

  • Placeholder

    Jorge Cortes, M.D., Acute Myeloid Leukemia Advisor

    Deputy Chair and Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center

  • Placeholder

    Steven I. Park, M.D., Lymphoma Advisor

    Division Chief, Hematology and Oncology, Levine Cancer Institute, CHS-Northeast; Director of Investigational Therapeutics in Hematologic Malignancies, Levine Cancer Institute/Carolinas HealthCare System; Associate Professor of Medicine, University of North Carolina, Chapel Hill

World Class Team

Innovation in oncology drug development requires a deep well of scientific, medical and business expertise, and we have assembled an unparalleled team of directors and advisors who will work with Cornerstone to revolutionize anticancer treatment.

Our Board of Directors and Scientific & Medical Advisory Boards are drawn from the highest echelons of oncology and hematology researchers and physicians, and include seasoned managers from the biotech and pharmaceutical sectors.


  • Placeholder

    Chi Van Dang, M.D., Ph.D., Chairman of Rafael’s Scientific and Medical Advisory Boards

    Director of the Abramson Cancer Center of the University of Pennsylvania. Dr. Dang is considered by many to be the world’s leading authority on cancer metabolism. Dr. Dang currently serves as Rafael’s Chairman of the Scientific and Medical Advisory Boards.

  • Placeholder

    Greg Semenza, M.D., Ph.D., Scientific Advisor

    Director, Vascular Program, Institute for Cell Engineering; Professor of Pediatrics, Radiation Oncology and Molecular Radiation Sciences, Biological Chemistry, Medicine, and Oncology at the Johns Hopkins University School of Medicine. Dr. Semenza won the 2016 Lasker Award.

  • Placeholder

    Dafna Bar-Sagi, Ph.D., Scientific Advisor

    Senior Vice President, Vice Dean for Science, Chief Scientific Officer, Professor, Departments of Biochemistry and Molecular Pharmacology, and Medicine, NYU Langone Medical Center

  • Placeholder

    Philip A. Philip, M.D., Ph.D., FRCP, Pancreatic Cancer Advisor

    Professor of Oncology and Pharmacology, Leader, GI and Neuroendocrine Oncology, Vice President of Medical Affairs, Karmanos Cancer Center, Wayne State University, Detroit, MI.

  • Placeholder

    Jorge Cortes, M.D., Acute Myeloid Leukemia Advisor

    Deputy Chair and Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center

  • Placeholder

    Steven I. Park, M.D., Lymphoma Advisor

    Division Chief, Hematology and Oncology, Levine Cancer Institute, CHS-Northeast; Director of Investigational Therapeutics in Hematologic Malignancies, Levine Cancer Institute/Carolinas HealthCare System; Associate Professor of Medicine, University of North Carolina, Chapel Hill

News & Events

June 14, 2018

Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613 in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association

June 4, 2018

Rafael Pharmaceuticals to Present at 2018 Bio International Conference

April 2018

A letter to shareholders, from Sanjeev Luther, Rafael Pharmaceuticals’ CEO

April 12, 2018

Clinical Cancer Research Publishes Phase I Data from a Study of Rafael Pharmaceuticals’ Lead CPI-613 Compound in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia

December 07, 2017

Rafael Pharmaceuticals to Present New Data Validating Efficacy of CPI-613 in Treating Acute Myeloid Leukemia at the 2017 American Society of Hematology Annual Meeting & Exposition

November 16, 2017

Rafael Pharmaceuticals, in Collaboration with Atlantic Health System, Announces Initiation of a Phase I Study of CPI-613 in Combination with Gemcitabine and Nab-Paclitaxel for Patients with Locally Advanced or Metastatic Pancreatic Cancer